Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00601692 |
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Irinotecan and docetaxel may also make tumor cells more sensitive to radiation therapy. Giving combination chemotherapy together with radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when given together with irinotecan and radiation therapy with or without cisplatin in treating patients with locally advanced esophageal cancer.
Condition | Intervention | Phase |
---|---|---|
Esophageal Cancer |
Drug: cisplatin Drug: docetaxel Drug: irinotecan hydrochloride Radiation: radiation therapy |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase I Trial of Irinotecan, Radiation Therapy and Escalating Doses of Docetaxel With Cisplatin in Locally Advanced Esophageal Cancer |
Estimated Enrollment: | 36 |
Study Start Date: | April 2003 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Regimen 1: Experimental
Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: docetaxel
Given IV
Drug: irinotecan hydrochloride
Given IV
Radiation: radiation therapy
Given 5 days a week for 3 weeks
|
Regimen 2: Experimental
Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: cisplatin
Given IV
Drug: docetaxel
Given IV
Drug: irinotecan hydrochloride
Given IV
Radiation: radiation therapy
Given 5 days a week for 3 weeks
|
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients receive one of the following regimens. Regimen 2 is for patients recruited after the recommended phase II dose has been determined in patients recruited (who receive regimen 1).
Regimen 1:
Regimen 2:
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically confirmed squamous cell carcinoma, adenocarcinoma, poorly differentiated carcinoma, or carcinoma not otherwise specified, of the esophagus or gastroesophageal (GE) junction
M1a metastatic disease to lymph nodes allowed
Previously untreated patients with primary tumors of the cervical or thoracic esophagus, including the GE junction, are eligible for this study
Exclusion criteria:
PATIENT CHARACTERISTICS:
Inclusion criteria:
Exclusion criteria:
Severe comorbid conditions including, but not limited to, any of the following:
PRIOR CONCURRENT THERAPY:
United States, New York | |
Memorial Sloan-Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: David H. Ilson, MD, PhD 212-639-8306 |
Principal Investigator: | David H. Ilson, MD, PhD | Memorial Sloan-Kettering Cancer Center |
Study ID Numbers: | CDR0000582309, MSKCC-02061, SANOFI-AVENTIS-MSKCC-02061 |
Study First Received: | January 17, 2008 |
Last Updated: | April 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00601692 History of Changes |
Health Authority: | Unspecified |
squamous cell carcinoma of the esophagus adenocarcinoma of the esophagus stage II esophageal cancer stage III esophageal cancer stage IV esophageal cancer |
Digestive System Neoplasms Gastrointestinal Diseases Esophageal Neoplasms Irinotecan Esophageal Cancer Squamous Cell Carcinoma Camptothecin Carcinoma Docetaxel Digestive System Diseases |
Radiation-Sensitizing Agents Cisplatin Esophageal Disorder Head and Neck Neoplasms Epidermoid Carcinoma Gastrointestinal Neoplasms Esophageal Diseases Carcinoma, Squamous Cell Adenocarcinoma Antineoplastic Agents, Phytogenic |
Digestive System Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Gastrointestinal Diseases Esophageal Neoplasms Physiological Effects of Drugs Irinotecan Enzyme Inhibitors Pharmacologic Actions Camptothecin Docetaxel |
Neoplasms Digestive System Diseases Neoplasms by Site Radiation-Sensitizing Agents Cisplatin Therapeutic Uses Head and Neck Neoplasms Gastrointestinal Neoplasms Esophageal Diseases Antineoplastic Agents, Phytogenic |